The results highlight the commercial success of PAPZIMEOS, the first FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP) ... This data set a new benchmark for RRP therapies.
INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often requires surgeryVOCERYQ™ is a plasmid DNA-based immunotherapy that targets the root cause of RRP.